25 results
Adbry (tralokinumab-ldrm)
(tralokinumab-ldrm)LEO Pharma Inc.
Usage: ADBRY is indicated for treating moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years and older when topical prescription therapies are insufficient or unsuitable. It can be used alone or in conjunction with topical corticosteroids.
Cibinqo (abrocitinib)
(abrocitinib)Pfizer Laboratories Div Pfizer Inc
Usage: CIBINQO is indicated for treating adults and pediatric patients aged 12 and older with refractory, moderate-to-severe atopic dermatitis not adequately controlled by other systemic treatments, including biologics, or when those therapies are inadvisable. It is not recommended for use with other JAK inhibitors or immunosuppressants.
Cibinqo (abrocitinib)
(abrocitinib)U.S. Pharmaceuticals
Usage: CIBINQO is indicated for treating adults and pediatric patients (12 years and older) with refractory, moderate-to-severe atopic dermatitis not adequately controlled by other systemic treatments or where those therapies are inadvisable. It is not recommended for use with other JAK inhibitors or immunosuppressants.
Dexamethasone sodium phosphate (dexamethasone sodium phosphate)
(Dexamethasone Sodium Phosphate)Henry Schein, Inc.
Usage: This drug is indicated for various conditions such as endocrine disorders (e.g., adrenal insufficiency), rheumatic disorders (e.g., rheumatoid arthritis), allergic states, dermatologic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, neoplastic diseases, and cerebral edema. It can be administered via injection or intra-articular methods.
Dupixent (dupilumab)
(Dupilumab)sanofi-aventis U.S. LLC
Usage: DUPIXENT is indicated for treatment of moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease (COPD) in adults and pediatric patients, depending on the condition and age. It is not for acute bronchospasm relief.
Ebglyss (lebrikizumab-lbkz)
(lebrikizumab-lbkz)Eli Lilly and Company
Usage: EBGLYSS is indicated for adults and pediatric patients (12 years and older, weighing at least 40 kg) with moderate-to-severe atopic dermatitis not adequately controlled by topical therapies or when such therapies are inappropriate. It may be used alone or alongside topical corticosteroids.
Eucrisa (crisaborole)
(crisaborole)Pfizer Laboratories Div Pfizer Inc
Usage: EUCRISA is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients aged 3 months and older.
Fluocinolone acetonide (fluocinolone acetonide)
(fluocinolone acetonide)Padagis Israel Pharmaceuticals Ltd
Usage: Fluocinolone Acetonide Topical Oil, 0.01% is indicated for topical treatment of atopic dermatitis in adults and moderate to severe cases in pediatric patients aged 3 months and older for up to 4 weeks. Safety in children under 3 months is not established.
Fluocinolone acetonide (fluocinolone acetonide)
(fluocinolone acetonide)Bryant Ranch Prepack
Usage: Fluocinolone Acetonide Topical Oil, 0.01% is indicated for the topical treatment of atopic dermatitis in adults and moderate to severe atopic dermatitis in pediatric patients aged 3 months and older, for up to 4 weeks. Limited to non-occlusive areas, and should be used under medical guidance.
Fluocinolone acetonide (fluocinolone acetonide)
(fluocinolone acetonide)Bryant Ranch Prepack
Usage: Fluocinolone Acetonide Topical Oil, 0.01% is indicated for the topical treatment of atopic dermatitis in adults and moderate to severe atopic dermatitis in pediatric patients aged 3 months and older for up to 4 weeks. Use minimal amounts and avoid certain areas as directed.